{"log_id": 7633293757155296438, "direction": 0, "words_result_num": 48, "words_result": [{"probability": {"variance": 5.8e-05, "average": 0.996163, "min": 0.964035}, "location": {"width": 805, "top": 214, "height": 41, "left": 260}, "words": "另一试验提供了利奈唑胺治疗耐甲氧西林金黄色葡萄球菌(MRSA)感染的经验。这是"}, {"probability": {"variance": 1.3e-05, "average": 0.998463, "min": 0.979865}, "location": {"width": 643, "top": 252, "height": 35, "left": 215}, "words": "一项随机、开放试验,患者为确诊或怀疑MRSA感染的成年住院患者"}, {"probability": {"variance": 1.2e-05, "average": 0.998353, "min": 0.980247}, "location": {"width": 787, "top": 283, "height": 38, "left": 279}, "words": "组患者接受利奈唑胺静脉给药600mg每12小时一次,然后转成利奈唑胺片剂口服"}, {"probability": {"variance": 0.000849, "average": 0.989629, "min": 0.848869}, "location": {"width": 845, "top": 316, "height": 40, "left": 220}, "words": "00mg每12小时一次。另一组患者接受万古霉素静脉给药1g每12小时一次。二组患者治疗"}, {"probability": {"variance": 0.001811, "average": 0.992255, "min": 0.720074}, "location": {"width": 856, "top": 351, "height": 37, "left": 211}, "words": "7-28天。若临床需要,病人可合并应用氨曲南或庆大霉素。患MRSA皮肤和皮肤软组织感"}, {"probability": {"variance": 0.001545, "average": 0.984447, "min": 0.828467}, "location": {"width": 854, "top": 384, "height": 38, "left": 213}, "words": "染的、微生物学可评估患者的治愈率在利奈唑胺治疗组为26/33(79%),在万古霉素组为24/33"}, {"probability": {"variance": 4.1e-05, "average": 0.992603, "min": 0.986226}, "location": {"width": 19, "top": 430, "height": 19, "left": 236}, "words": "73"}, {"probability": {"variance": 0, "average": 0.999619, "min": 0.999087}, "location": {"width": 131, "top": 491, "height": 27, "left": 212}, "words": "糖尿病足感染"}, {"probability": {"variance": 0.002906, "average": 0.990272, "min": 0.666919}, "location": {"width": 793, "top": 516, "height": 38, "left": 255}, "words": "伴有临床已证实的复杂性皮肤和皮肤软组织感染(糖尿病足感染)的成年糖尿病患者"}, {"probability": {"variance": 0.000123, "average": 0.996323, "min": 0.947829}, "location": {"width": 849, "top": 550, "height": 37, "left": 211}, "words": "随机(按照2:1的比例)入选一个多中心、开放的对照临床研究,试验药物静脉或口服给药"}, {"probability": {"variance": 4.3e-05, "average": 0.996838, "min": 0.966224}, "location": {"width": 859, "top": 582, "height": 39, "left": 212}, "words": "总疗程14至28天。一组患者利奈唑胺静脉或口服给药600mg每12小时一次;另一组氨苄西"}, {"probability": {"variance": 0.000179, "average": 0.995209, "min": 0.927265}, "location": {"width": 860, "top": 617, "height": 35, "left": 212}, "words": "林/舒巴坦静脉给药1.5至3g或者阿莫西林克拉维酸口服500mg至875mg每8至12小时(q8"}, {"probability": {"variance": 0.00096, "average": 0.991175, "min": 0.820125}, "location": {"width": 827, "top": 649, "height": 35, "left": 243}, "words": "2h)一次。在氨苄西林/舒巴坦没有上市的国家,静脉给药选用阿莫西林/克拉维酸500mg"}, {"probability": {"variance": 0.000127, "average": 0.995476, "min": 0.93654}, "location": {"width": 861, "top": 680, "height": 38, "left": 210}, "words": "至2g每6小时(q6h)给药一次。对照组的患者如果足部感染部位检出MRSA,可用静脉给"}, {"probability": {"variance": 3e-06, "average": 0.99916, "min": 0.993445}, "location": {"width": 859, "top": 713, "height": 37, "left": 212}, "words": "予万古霉素1g每12小时一次。两组患者中,如果在感染部位分离出革兰阴性杆菌,可以给"}, {"probability": {"variance": 1.1e-05, "average": 0.998532, "min": 0.98553}, "location": {"width": 860, "top": 746, "height": 38, "left": 212}, "words": "予氨曲南1g至2g,每8至12小时一次。所有的患者可以接受适当的辅助治疗,治疗糖尿病"}, {"probability": {"variance": 4.2e-05, "average": 0.997653, "min": 0.959685}, "location": {"width": 859, "top": 778, "height": 38, "left": 207}, "words": "足感染的典型措施如:清创术和减负荷术,绝大多数患者接受了此类治疗。意向治疗(ITT)"}, {"probability": {"variance": 0.000269, "average": 0.994684, "min": 0.891735}, "location": {"width": 861, "top": 811, "height": 37, "left": 210}, "words": "人群包括,241例利奈唑胺治疗和120例对照药物治疗的患者。212例(86%)利奈唑胺治疗"}, {"probability": {"variance": 4.3e-05, "average": 0.997741, "min": 0.961696}, "location": {"width": 862, "top": 845, "height": 34, "left": 210}, "words": "组患者和105例(85%)对照药物治疗组患者作为临床可评估患者。ITT人群的治愈率,在"}, {"probability": {"variance": 0.001884, "average": 0.982978, "min": 0.793944}, "location": {"width": 866, "top": 876, "height": 37, "left": 208}, "words": "利奈唑胺治疗组患者为68.5%(165/241),对照药物组为64%(77120),评价时将不能判定和"}, {"probability": {"variance": 3.4e-05, "average": 0.998124, "min": 0.969816}, "location": {"width": 865, "top": 908, "height": 37, "left": 208}, "words": "缺失的结果归为治疗失败。临床可评估的患者中(除外结果为不能判定和缺失的患者)的治"}, {"probability": {"variance": 0.000212, "average": 0.99443, "min": 0.909747}, "location": {"width": 865, "top": 940, "height": 37, "left": 209}, "words": "愈率,在利奈唑胺治疗组为83%(159192),在对照药物组为73%(74/101)。一项重要的"}, {"probability": {"variance": 0.000838, "average": 0.990974, "min": 0.858191}, "location": {"width": 824, "top": 973, "height": 35, "left": 252}, "words": "hoc分析,针对从感染部位或血液中分离出革兰阳性菌的患者,利奈唑胺组121例,对照"}, {"probability": {"variance": 8e-06, "average": 0.998721, "min": 0.983703}, "location": {"width": 850, "top": 1004, "height": 38, "left": 206}, "words": "组60例,较总体研究人群,这些患者更少有伴发骨髓炎的证据且没有应用被禁用的抗生素"}, {"probability": {"variance": 0.004909, "average": 0.985927, "min": 0.506356}, "location": {"width": 870, "top": 1038, "height": 37, "left": 207}, "words": "根据该分析,利奈唑胺治疗的患者治愈率为71%(86121),对照药物组为63%(38160)。未根"}, {"probability": {"variance": 2.1e-05, "average": 0.99847, "min": 0.971374}, "location": {"width": 825, "top": 1070, "height": 39, "left": 205}, "words": "据辅助治疗对于上述分析进行调整。微生物学可评估患者中不同病原菌的治愈率见表14"}, {"probability": {"variance": 0.000459, "average": 0.993427, "min": 0.875219}, "location": {"width": 710, "top": 1136, "height": 36, "left": 286}, "words": "表14微生物学可评估的糖尿病足感染成年患者治愈检测随访时的治愈率"}, {"probability": {"variance": 0, "average": 0.999185, "min": 0.998583}, "location": {"width": 57, "top": 1181, "height": 22, "left": 320}, "words": "病原体"}, {"probability": {"variance": 0, "average": 0.999775, "min": 0.999557}, "location": {"width": 75, "top": 1178, "height": 21, "left": 743}, "words": "治愈"}, {"probability": {"variance": 5e-06, "average": 0.995271, "min": 0.992797}, "location": {"width": 73, "top": 1217, "height": 22, "left": 568}, "words": "利奈唑胺"}, {"probability": {"variance": 4e-06, "average": 0.998871, "min": 0.994735}, "location": {"width": 101, "top": 1214, "height": 22, "left": 857}, "words": "对照药物n/"}, {"probability": {"variance": 0.000395, "average": 0.986477, "min": 0.954888}, "location": {"width": 130, "top": 1258, "height": 22, "left": 217}, "words": "金黄色葡萄球菌"}, {"probability": {"variance": 0.000802, "average": 0.982404, "min": 0.912112}, "location": {"width": 72, "top": 1253, "height": 19, "left": 885}, "words": "20/29(69"}, {"probability": {"variance": 2e-06, "average": 0.998829, "min": 0.995241}, "location": {"width": 227, "top": 1288, "height": 25, "left": 215}, "words": "耐甲氧西林金黄色葡萄球菌"}, {"probability": {"variance": 1.3e-05, "average": 0.995956, "min": 0.990521}, "location": {"width": 52, "top": 1287, "height": 20, "left": 903}, "words": "/3(67)"}, {"probability": {"variance": 0, "average": 0.999343, "min": 0.998401}, "location": {"width": 92, "top": 1326, "height": 21, "left": 219}, "words": "无乳链球菌"}, {"probability": {"variance": 0.003975, "average": 0.955504, "min": 0.847504}, "location": {"width": 39, "top": 1322, "height": 17, "left": 910}, "words": "6(56"}, {"probability": {"variance": 1.3e-05, "average": 0.997601, "min": 0.989629}, "location": {"width": 263, "top": 1392, "height": 28, "left": 205}, "words": "万古霉素耐药的肠球菌感染"}, {"probability": {"variance": 1e-05, "average": 0.998668, "min": 0.982488}, "location": {"width": 828, "top": 1419, "height": 34, "left": 250}, "words": "明确或怀疑为万古霉素耐药的肠球菌感染的成年患者入选至一个随机、多中心、双盲对"}, {"probability": {"variance": 0.00015, "average": 0.996623, "min": 0.918976}, "location": {"width": 880, "top": 1450, "height": 38, "left": 201}, "words": "照的研究中,以高剂量利奈唑胺(600mg每12小时一次,口服或静注)或低剂量利奈唑胺"}, {"probability": {"variance": 0.007634, "average": 0.98359, "min": 0.418027}, "location": {"width": 854, "top": 1483, "height": 38, "left": 224}, "words": "200mg每12小时一次,口服或静注)治疗728天。患者可合并应用氨曲南或氨基糖苷类"}, {"probability": {"variance": 1.2e-05, "average": 0.998854, "min": 0.977522}, "location": {"width": 874, "top": 1517, "height": 38, "left": 204}, "words": "抗生素。79例患者随机进入高剂量组,66例患者随机进入低剂量组。基线已确定为万古霉素"}, {"probability": {"variance": 0.015344, "average": 0.953926, "min": 0.518933}, "location": {"width": 300, "top": 1558, "height": 26, "left": 200}, "words": "耐药肠球菌感染的意向治疗(In"}, {"probability": {"variance": 0.001397, "average": 0.984405, "min": 0.830305}, "location": {"width": 462, "top": 1550, "height": 34, "left": 616}, "words": "ITT)人群包括高剂量组的65人和低剂量组的52"}, {"probability": {"variance": 0, "average": 0.997424, "min": 0.997424}, "location": {"width": 26, "top": 1594, "height": 24, "left": 198}, "words": "人"}, {"probability": {"variance": 2.8e-05, "average": 0.997332, "min": 0.982444}, "location": {"width": 153, "top": 1626, "height": 24, "left": 564}, "words": "第20页,共29页"}, {"probability": {"variance": 0.015904, "average": 0.920126, "min": 0.656328}, "location": {"width": 113, "top": 1653, "height": 20, "left": 581}, "words": "辉瑞——机密"}, {"probability": {"variance": 2.3e-05, "average": 0.993814, "min": 0.988992}, "location": {"width": 17, "top": 1681, "height": 18, "left": 295}, "words": "20"}], "language": 3}